Cargando…

WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea

Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are i...

Descripción completa

Detalles Bibliográficos
Autor principal: Jeon, Doosoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617849/
https://www.ncbi.nlm.nih.gov/pubmed/28905529
http://dx.doi.org/10.4046/trd.2017.0049
_version_ 1783267052977389568
author Jeon, Doosoo
author_facet Jeon, Doosoo
author_sort Jeon, Doosoo
collection PubMed
description Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are intended to improve detection rate and treatment outcome for MDR-TB through novel, rapid molecular testing and shorter treatment regimens. Key changes include the introduction of a new, shorter MDR-TB treatment regimen, a new classification of medicines and updated recommendations for the conventional MDR-TB regimen. This paper will review these key changes and discuss the potential issues with regard to the implementation of these guidelines in South Korea.
format Online
Article
Text
id pubmed-5617849
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Korean Academy of Tuberculosis and Respiratory Diseases
record_format MEDLINE/PubMed
spelling pubmed-56178492017-10-01 WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea Jeon, Doosoo Tuberc Respir Dis (Seoul) Review Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are intended to improve detection rate and treatment outcome for MDR-TB through novel, rapid molecular testing and shorter treatment regimens. Key changes include the introduction of a new, shorter MDR-TB treatment regimen, a new classification of medicines and updated recommendations for the conventional MDR-TB regimen. This paper will review these key changes and discuss the potential issues with regard to the implementation of these guidelines in South Korea. The Korean Academy of Tuberculosis and Respiratory Diseases 2017-10 2017-09-01 /pmc/articles/PMC5617849/ /pubmed/28905529 http://dx.doi.org/10.4046/trd.2017.0049 Text en Copyright©2017. The Korean Academy of Tuberculosis and Respiratory Diseases http://creativecommons.org/licenses/by-nc/4.0/ It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Review
Jeon, Doosoo
WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
title WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
title_full WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
title_fullStr WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
title_full_unstemmed WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
title_short WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
title_sort who treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in south korea
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617849/
https://www.ncbi.nlm.nih.gov/pubmed/28905529
http://dx.doi.org/10.4046/trd.2017.0049
work_keys_str_mv AT jeondoosoo whotreatmentguidelinesfordrugresistanttuberculosis2016updateapplicabilityinsouthkorea